PARP inhibition sensitizes endometrial cancer cells to paclitaxel-induced apoptosis

  • Authors:
    • Christine Dinkic
    • Friederike Jahn
    • Marek Zygmunt
    • Florian Schuetz
    • Joachim Rom
    • Christof Sohn
    • Herbert Fluhr
  • View Affiliations

  • Published online on: March 1, 2017     https://doi.org/10.3892/ol.2017.5795
  • Pages: 2847-2851
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

PARP inhibitors are used in the treatment of gynecological malignancies and it has been demonstrated in preclinical studies that PARP inhibition sensitizes cancer cells to cytotoxic agents. In the present study, PARP expression was detected in different endometrial cancer cell lines by western blot analysis, and PARP activity was measured using an enzymatic assay. In addition, the endometrial cancer cell lines were treated with paclitaxel or carboplatin in combination with the PARP inhibitor PJ34 prior to a cell viability assay and apoptotic nuclei measurement. PARP protein was detected in all four cell lines examined, although its activity varied between the cell lines. Treatment with PJ34 in combination with paclitaxel decreased endometrial cancer cell viability compared with treatment with paclitaxel alone. These results indicate that the inhibition of PARP with PJ34 sensitizes endometrial cancer cells to cytotoxic treatment with paclitaxel.

Related Articles

Journal Cover

April-2017
Volume 13 Issue 4

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Dinkic C, Jahn F, Zygmunt M, Schuetz F, Rom J, Sohn C and Fluhr H: PARP inhibition sensitizes endometrial cancer cells to paclitaxel-induced apoptosis. Oncol Lett 13: 2847-2851, 2017
APA
Dinkic, C., Jahn, F., Zygmunt, M., Schuetz, F., Rom, J., Sohn, C., & Fluhr, H. (2017). PARP inhibition sensitizes endometrial cancer cells to paclitaxel-induced apoptosis. Oncology Letters, 13, 2847-2851. https://doi.org/10.3892/ol.2017.5795
MLA
Dinkic, C., Jahn, F., Zygmunt, M., Schuetz, F., Rom, J., Sohn, C., Fluhr, H."PARP inhibition sensitizes endometrial cancer cells to paclitaxel-induced apoptosis". Oncology Letters 13.4 (2017): 2847-2851.
Chicago
Dinkic, C., Jahn, F., Zygmunt, M., Schuetz, F., Rom, J., Sohn, C., Fluhr, H."PARP inhibition sensitizes endometrial cancer cells to paclitaxel-induced apoptosis". Oncology Letters 13, no. 4 (2017): 2847-2851. https://doi.org/10.3892/ol.2017.5795